Looking ahead after 50 years of research on cannabinoids

Cannabinoids

Volumn , Issue , 2014, Pages 1-15

  Mechoulam, Raphael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Amino acids; Cannabidiol (CBD); Cannabinoids; Endogenous molecules; Fatty acid amides

Indexed keywords

EID: 84947567839     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118451281.ch1     Document Type: Chapter

References (81)

1. Ben-Shabat, S., Fride, E., Sheskin, T., et al (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol., (353), 23-31.
2. Bradshaw, H.B., Rimmerman, N., Hu, S.S., et al. (2009) Novel endogenous N-acyl glycines identification and characterization. Vitam Horm., 81, 191-205.
3. Brady, K.T. and Balster, R.L (1980) The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacol (Berl), 72, 21-26.
4. Brown, I., Cascio, M.G., Wahle, K.W., et al (2010) Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis, 31, 1584-1591.
5. Campos, A.C., Moreira, F.A., Gomes, F.V., et al (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci., 367, 3364-3378.
6. Carrier, E.J., Auchampach, J.A. and Hillard, C.J (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA., 103, 7895-7900.
7. Casarotto, P.C., Gomes, F.V., Resstel, L.B. and Guimarães, F.S (2010) Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol., 21, 353-358.
8. Chatzakos, V., Slätis, K., Djureinovic, T., et al (2012) N-acyl taurines are antiproliferative in prostate cancer cells. Lipids, 47, 355-361.
9. Cohen-Yeshurun, A., Trembovler, V., Alexandrovich, A., et al (2011) N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab., 31, 1768-1777.
10. Cohen-Yeshurun, A.,Willner, D., Trembovler, V., et al (2013) N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab., 33, 1242-1250.
11. De Petrocellis, L., Orlando, P.,Moriello, A.S., et al (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf)., 204, 255-266.
12. Devane, W.A., Dysarz, F.A. 3rd, Johnson, M.R., et al (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol., 34, 605-613.
13. Devane,W.A., Breuer, A., Sheskin, T., et al. (1992) A novel probe for the cannabinoid receptor. J Med Chem., 35, 2065-2069.
14. Devane, W.A., Hanus, L., Breuer, A., et al. (1992b) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
15. Espejo-Porras, F., Fernández-Ruiz, J., Pertwee, R.G., et al (2013) Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacol., 75, 155-163.
16. Fernández-Ruiz, J., Sagredo, O., Pazos,M.R., et al. (2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol., 75, 323-333.
17. Fride, E. and Mechoulam, R (1993) Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur J Pharmacol., 231, 313-314.
18. Fride, E., Ginzburg, Y., Breuer, A., et al (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol., 419, 207-214.
19. Fu, J., Oveisi, F., Gaetani, S., et al (2005) Oleoylethanolamide, an endogenous PPAR-alpha agonist lowers body weight and hyperlipidemia in obese rats. Neuropharmacol., 48, 1147-1153.
20. Gaoni,Y. and Mechoulam, R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Amer Chem Soc., 86, 1646-1647.
21. Gomes, F.V., Resstel, L.B. and Guimarães, F.S (2011) The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacol (Berl)., 213, 465-473.
22. Hampson, A.J., Grimaldi, M., Lolic, M., et al (2000) Neuroprotective antioxidants from marijuana. Ann NY Acad Sci., 899, 274-282.
23. Hansen, H.S (2010) Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol., 224, 48-55.
24. Hanus, L., Breuer, A., Tchilibon, S., et al (1999) HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA., 96, 14228-14233.
25. Juknat, A., Rimmerman, N., Levy, R., et al (2012) Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem Int., 61, 923-930.
26. Juknat, A., Pietr, M., Kozela, E., et al. (2013) Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS One, 8, e61462.
27. Katsidoni, V., Anagnostou, I. and Panagis, G (2013) Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol., 18, 286-296.
28. Kozela, E., Juknat, A., Kaushansky, N., et al. (2013) Cannabinoids decrease the Th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol. [Epub ahead of print].
29. Leweke, F.M., Piomelli, D., Pahlisch, F., et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, e94.
30. Loewe, S (1950) Cannabiswirkstoffe und pharmacologie der cannabinole. Arch Exp Pathol Pharmacol., 211, 175-189.
31. Maccarrone, M., Pauselli, R., Di Rienzo, M. and Finazzi-Agro, A. (2002) Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J., 366(Pt. 1), 137-144.
32. Magen, I., Avraham, Y., Ackerman, Z., et al (2010) Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol., 159, 950-957.
33. Malfait, A.M., Gallily, R., Sumariwalla, P.F., et al (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA., 97, 9561-9566.
34. Marinelli, S., DiMarzo, V., Florenzano, F., et al (2007) N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacol., 32, 298-308.
35. Mechoulam, R. Ed. (1973) Marijuana. Chemistry, Metabolism, Pharmacology and Clinical Effects. Academic Press, New York.
36. Mechoulam, R. and Shvo, Y (1963) The structure of cannabidiol. Tetrahedron., 19, 2073-2078.
37. Mechoulam, R. and Gaoni, Y. (1967a) Recent advances in the chemistry of hashish. In: Fortschritte der Chemie Organischer Naturstoffe (Zechmeister, L. Ed.) 25, 175-213.
38. 1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett., 12, 1109-1111.
39. Mechoulam, R. and Parker, L.A. (2013) The endocannabinoid system and the brain. Annu Rev Psychol., 64: 21-47.
40. 6-tetrahydrocannabinols. J Amer Chem. Soc., 89, 4552-4554.
41. Mechoulam, R., Shani, A., Edery, H. and Grunfeld, Y (1970) The chemical basis of hashish activity. Science, 169, 611-612.
42. Mechoulam, R., McCallum, N.K. and Burstein, S. (1976). Recent advances in the chemistry and biochemistry of cannabis. Chem. Revs., 76, 75-112.
43. Mechoulam, R., Lander, N., Srebnik, M., et al. (1987) Stereochemical requirements for cannabimimetic activity. In: Structure Activity Relationships of the Cannabinoids (Rapaka, R.S. and Makriyannis, A.) National Institute on Drug Abuse. Monograph 79 Washington DC.
44. Mechoulam, R., Feigenbaum, J.J., Lander, N., et al. (1988). Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia, 44, 762-764.
45. Mechoulam, R. Ben-Shabat, S., Hanus, L., et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol., 50, 83-90.
46. Mechoulam, R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2009) Cannabidiol-recent advances. In: Cannabinoids in Nature and Medicine (D.M. Lambert Ed.) Wiley-VCH.
47. Milman, G., Maor, Y., Abu-Lafi, S., et al (2006) N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA., 103, 2428-2433.
48. Morgan, C.J., Gardener, C., Schafer, G., et al (2012) Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med., 42, 391-400.
49. Moreau, J.J. (1973) Hashish and Mental Illness. New York, NY: Raven Press.
50. Morgan, C.J., Schafer, G., Freeman, T.P. and Curran, H.V (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study. Br J Psychiatry, 197, 285-290.
51. Naccarato, M., Pizzuti, D., Petrosino, S., et al (2010) Possible anandamide and palmitoylethanolamide involvement in human stroke. Lipids Health Dis., 9, 47-53.
52. Pacher, P. and Mechoulam, R. (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res., 50, 193-211.
53. Pacher, P and Kunos, G (2013) Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J., 280, 1918-1943.
54. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., et al (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 413, 527-531.
55. 1 receptor-dependent manner. J Biol Chem., 283, 6005-6012.
56. 2 receptors. Neuropharmacol., 71, 282-291.
57. Pucci, M., Rapino, C., Di Francesco, A., et al (2013) Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol., 170, 581-591.
58. Qin, N., Neeper, M.P., Liu, Y., et al (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci., 28, 6231-6238.
59. Resstel, L.B., Tavares, R.F., Lisboa, S.F., et al (2009) 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol., 156, 181-188.
60. Robson, P (2011) Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf., 10, 675-685.
61. Rock, E.M., Bolognini, D., Limebeer, C.L., et al (2012) Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol., 165, 2620-2634.
62. Scopinho, A.A., Guimarães, F.S., Corrêa, F.M. and Resstel, L.B (2011) Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists. Pharmacol Biochem Behav., 98, 268-272.
63. Sulcova, E., Mechoulam, R. and Fride, E (1998) Biphasic effects of anandamide. Pharmacol Biochem Behav., 59, 347-352.
64. Schoedel, K.A., Chen, N., Hilliard, A., et al (2011) A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol., 26, 224-236.
65. Sheskin, T., Hanus, L., Slager, J., et al (1997) Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem., 40, 659-667.
66. Smith, P.B., Compton, D.R., Welch, S.P., et al (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther., 270, 219-227.
67. Smoum, R., Bar, A., Tan, B., et al (2010) Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci USA., 107, 17710-17715.
68. Soroceanu, L., Murase, R., Limbad, C., et al (2013) Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res., 73, 1559-15569.
69. 9Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. J Psychopharmacol., 26, 1299-1306.
70. Tan, B., O'Dell, D.K., Yu, Y.W., et al (2010) Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res., 51, 112-119.
71. Tan, B., Yu, Y.W., Monn, M.F., et al (2009) Targeted lipidomics approach for endogenous N-acyl amino acids in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci., 877, 2890-2894.
72. Tortoriello, G., Rhodes, B.P., Takacs, S.M., et al. (2013) Targeted lipidomics in Drosophila melanogaster identifies novel monoacylglycerols and N-acyl amides. PLoS One, 8, e67865.
73. Twardowschy, A., Castiblanco-Urbina, M.A., Uribe-Mariño, A., et al (2013) The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae). J Psychopharmacol., 27, 1149-1159.
74. Ugdyzhekova, D.S., Davydova, Y.G., Maimeskulova, L.A. and Mechoulam, R (2000) Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. Bull. Exp. Biol. Med., 130, 1087-1089.
75. Vann, R.E., Gamage, T.F., Warner, J.A., et al (2008) Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend., 94, 191-198.
76. Vogel, Z., Barg, J., Levy, R., et al (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem., 61, 352-355.
77. Wade, D.T., Makela, P., Robson, P., et al (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler., 10, 434-441.
78. Weickert, C.S., Tiwari ,Y., Schofield, P.R., et al. (2012) Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Transl Psychiatry, 2, e104.
79. 9-tetrahydrocannabinol. Br J Pharmacol., [Epub ahead of print].
80. Xiong, W., Cui, T., Cheng, K., et al (2012) Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors. J ExpMed, 209, 1121-1134.
81. Zuardi, A.W., Hallak, J.E. and Crippa, J.A (2012) Interaction between cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacol (Berl), 219, 247-249.